These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 15842575

  • 1. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.
    Hawkey C, Talley NJ, Yeomans ND, Jones R, Sung JJ, Långström G, Naesdal J, Scheiman JM, NASA1 SPACE1 Study Group.
    Am J Gastroenterol; 2005 May; 100(5):1028-36. PubMed ID: 15842575
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs.
    Hawkey CJ, Jones RH, Yeomans ND, Scheiman JM, Talley NJ, Goldstein JL, Ahlbom H, Naesdal J.
    Aliment Pharmacol Ther; 2007 Apr 01; 25(7):813-21. PubMed ID: 17373920
    [Abstract] [Full Text] [Related]

  • 3. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.
    Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, Rainoldi JL, Szczepanski L, Ung KA, Kleczkowski D, Ahlbom H, Naesdal J, Hawkey C.
    Am J Gastroenterol; 2006 Apr 01; 101(4):701-10. PubMed ID: 16494585
    [Abstract] [Full Text] [Related]

  • 4. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D.
    J Rheumatol; 2002 Mar 01; 29(3):467-73. PubMed ID: 11908558
    [Abstract] [Full Text] [Related]

  • 5. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
    Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ, Lanas A, Agewall S, Nauclér EC, Svedberg LE, Nagy P.
    J Cardiovasc Pharmacol; 2013 Mar 01; 61(3):250-7. PubMed ID: 23188121
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin.
    Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Rácz I, Tchernev K, Karamanolis D, Roda E, Hawkey C, Nauclér E, Svedberg LE.
    Am J Gastroenterol; 2008 Oct 01; 103(10):2465-73. PubMed ID: 18637091
    [Abstract] [Full Text] [Related]

  • 7. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 01; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 8. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L.
    Semin Arthritis Rheum; 2002 Dec 01; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [Abstract] [Full Text] [Related]

  • 9. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies.
    Hawkey CJ, Talley NJ, Scheiman JM, Jones RH, Långström G, Naesdal J, Yeomans ND, NASA/SPACE author group.
    Arthritis Res Ther; 2007 Dec 01; 9(1):R17. PubMed ID: 17391505
    [Abstract] [Full Text] [Related]

  • 10. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial.
    van Zanten SV, Armstrong D, Chiba N, Flook N, White RJ, Chakraborty B, Gasco A.
    Am J Gastroenterol; 2006 Sep 01; 101(9):2096-106. PubMed ID: 16817845
    [Abstract] [Full Text] [Related]

  • 11. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.
    Gastroenterology; 2003 Feb 01; 124(2):288-92. PubMed ID: 12557133
    [Abstract] [Full Text] [Related]

  • 12. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.
    Gold BD, Gunasekaran T, Tolia V, Wetzler G, Conter H, Traxler B, Illueca M.
    J Pediatr Gastroenterol Nutr; 2007 Nov 01; 45(5):520-9. PubMed ID: 18030228
    [Abstract] [Full Text] [Related]

  • 13. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.
    Cryer BL, Sostek MB, Fort JG, Svensson O, Hwang C, Hochberg MC.
    Ann Med; 2011 Dec 01; 43(8):594-605. PubMed ID: 22017620
    [Abstract] [Full Text] [Related]

  • 14. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
    Rabeneck L, Goldstein JL, Vu A, Mayne TJ, Rublee DA.
    Am J Gastroenterol; 2005 May 01; 100(5):1043-50. PubMed ID: 15842577
    [Abstract] [Full Text] [Related]

  • 15. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.
    Johnson DA, Orr WC, Crawley JA, Traxler B, McCullough J, Brown KA, Roth T.
    Am J Gastroenterol; 2005 Sep 01; 100(9):1914-22. PubMed ID: 16128933
    [Abstract] [Full Text] [Related]

  • 16. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial.
    Goldstein JL, Johanson JF, Suchower LJ, Brown KA.
    Am J Gastroenterol; 2005 Dec 01; 100(12):2650-7. PubMed ID: 16393215
    [Abstract] [Full Text] [Related]

  • 17. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL, Eisen GM, Agrawal N, Stenson WF, Kent JD, Verburg KM.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):527-38. PubMed ID: 15339324
    [Abstract] [Full Text] [Related]

  • 18. The multisystem adverse effects of NSAID therapy.
    James DS.
    J Am Osteopath Assoc; 1999 Nov 01; 99(11 Suppl):S1-7. PubMed ID: 10643174
    [Abstract] [Full Text] [Related]

  • 19. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ, Hwang C, Datto C, Desai B, Sostek M.
    Clin Ther; 2011 Dec 01; 33(12):1883-93. PubMed ID: 22078153
    [Abstract] [Full Text] [Related]

  • 20. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
    Pavelka K, Recker DP, Verburg KM.
    Rheumatology (Oxford); 2003 Oct 01; 42(10):1207-15. PubMed ID: 12810937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.